Siglecs have long been associated with cancer: CD22 and CD33 are specific markers for B-cell lymphoma (5, 6) and anti-CD22 and anti-CD33 antibody therapies have also been used in clinical trials of B-cell lymphoma and myeloid leukemia (7). This evidence concerns the gene CD22 and myeloid leukemia.